bpc 2008 presentation sulaf3

18
S. Assi, R. Watt, A.C. Moffat Assay of Ciprofloxacin in Intact and Powdered Tablets by Near-infrared Spectroscopy The School of Pharmacy- University of London 29/39 Brunswick Square London-United Kingdom WC1N 1AX

Upload: sulafassi

Post on 09-Jun-2015

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Bpc 2008 Presentation Sulaf3

S. Assi, R. Watt, A.C. Moffat

Assay of Ciprofloxacin in Intact and Powdered Tablets by Near-infrared

Spectroscopy

The School of Pharmacy- University of London

29/39 Brunswick Square

London-United Kingdom

WC1N 1AX

Page 2: Bpc 2008 Presentation Sulaf3

Active Ingredient Excipients

Packaging Source

Counterfeit Medicine

Page 3: Bpc 2008 Presentation Sulaf3

API Assay in literature (1)

Chromatographic

Hyphenated

Spectroscopic

Near-infrared spectroscopy (NIRS)

Chemometrics: Partial Least Square

Regression (PLSR, MLR)

Quick, simple, accurate, non-

destructive

Page 4: Bpc 2008 Presentation Sulaf3

API Assay in literature (2)

Paracetamol

Ibuprofen

Macrolides

PLSR and MLR used in NIR

Quantified proprietary

Used more than one brand to

quantify generics

Page 5: Bpc 2008 Presentation Sulaf3

Quantify ciprofloxacin in generics

Use one brand only (Bayer’s Ciproxin)

Minimum or no sample treatment

Use the minimum amount of active or excipients

Use a range of active from 0 up to 100 %

Aim of the work:

Page 6: Bpc 2008 Presentation Sulaf3

Experimental (1)

MethodSample Preparation

• Tablets • Powdered mixtures • Pellets

NIR measurement

Spectra TreatmentPre-treatment (SNV-D2)

Quantitative model development

Page 7: Bpc 2008 Presentation Sulaf3

Experimental (2)

Page 8: Bpc 2008 Presentation Sulaf3

Experimental (3)

Quantitative Model Development

Page 9: Bpc 2008 Presentation Sulaf3

Results and Discussion (1)

Calibration and validation sets

Number of factors

Model quality (correlation coefficient, SEC, SEP)

Model selection (1)

Page 10: Bpc 2008 Presentation Sulaf3

Results and Discussion (2)

Model selection (2)

Page 11: Bpc 2008 Presentation Sulaf3

PLSR Loadings

Results and Discussion (3)

Page 12: Bpc 2008 Presentation Sulaf3

Results and Discussion (4)

Model Prediction (1)

Page 13: Bpc 2008 Presentation Sulaf3

Results and Discussion (5)

Effect of adding 0 and 100 % to the models (1)

Better prediction for intact tablets

The best type of zero used was erythromycin tablet

rather than excipient

The optimum number of zeros to be used is one

Page 14: Bpc 2008 Presentation Sulaf3

Results and Discussion (6)Effect of adding 0 and 100 % to the models (2)

Page 15: Bpc 2008 Presentation Sulaf3

Effect of adding 0 and 100 % to the models (3)

Results and Discussion (7)

Page 16: Bpc 2008 Presentation Sulaf3

CONCLUSION

NIR measurement with PLSR could quantify active in one

generics by diluting one proprietary type only with active or

excipient(s).

No or minimal sample treatment is required .

Addition of 0 and 100 % to Ciproxin standard addition model

improved the model so it could predict intact tablets.

Page 17: Bpc 2008 Presentation Sulaf3

Acknowledgement

The School of Pharmacy-University of London

FOSS COMPANY for the FOSS NIR 6500

Lebanese National Council for Scientific Research

Tanzanian Food and Drug Adminstration

Page 18: Bpc 2008 Presentation Sulaf3

Thank You For Thank You For Your AttentionYour Attention

[email protected]